Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1953 2
1954 1
1955 1
1956 1
1961 5
1962 6
1963 6
1964 6
1965 22
1966 12
1967 11
1968 4
1969 26
1970 16
1971 13
1972 14
1973 27
1974 29
1975 32
1976 30
1977 35
1978 33
1979 28
1980 40
1981 29
1982 39
1983 51
1984 57
1985 72
1986 59
1987 69
1988 86
1989 81
1990 91
1991 72
1992 78
1993 77
1994 83
1995 98
1996 113
1997 115
1998 132
1999 124
2000 134
2001 151
2002 153
2003 174
2004 167
2005 182
2006 188
2007 192
2008 206
2009 219
2010 250
2011 258
2012 320
2013 281
2014 266
2015 244
2016 278
2017 309
2018 324
2019 352
2020 368
2021 397
2022 402
2023 94
Text availability
Article attribute
Article type
Publication date

Search Results

7,180 results
Results by year
Filters applied: . Clear all
Page 1
Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma.
Yamagishi R, Kamachi F, Nakamura M, Yamazaki S, Kamiya T, Takasugi M, Cheng Y, Nonaka Y, Yukawa-Muto Y, Thuy LTT, Harada Y, Arai T, Loo TM, Yoshimoto S, Ando T, Nakajima M, Taguchi H, Ishikawa T, Akiba H, Miyake S, Kubo M, Iwakura Y, Fukuda S, Chen WY, Kawada N, Rudensky A, Nakae S, Hara E, Ohtani N. Yamagishi R, et al. Among authors: ishikawa t. Sci Immunol. 2022 Jun 24;7(72):eabl7209. doi: 10.1126/sciimmunol.abl7209. Epub 2022 Jun 24. Sci Immunol. 2022. PMID: 35749514
Endoscopic management of perihilar cholangiocarcinoma.
Kawashima H, Ohno E, Ishikawa T, Mizutani Y, Iida T, Yamamura T, Kakushima N, Furukawa K, Nakamura M. Kawashima H, et al. Among authors: ishikawa t. Dig Endosc. 2022 Sep;34(6):1147-1156. doi: 10.1111/den.14317. Epub 2022 Jun 2. Dig Endosc. 2022. PMID: 35377509 Review.
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Yamaguchi J, Yokoyama Y, Fujii T, Yamada S, Takami H, Kawashima H, Ohno E, Ishikawa T, Maeda O, Ogawa H, Kodera Y, Nagino M, Ebata T. Yamaguchi J, et al. Among authors: ishikawa t. Ann Surg. 2022 Jun 1;275(6):1043-1049. doi: 10.1097/SLA.0000000000005430. Epub 2022 Mar 3. Ann Surg. 2022. PMID: 35258510 Clinical Trial.
Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics.
Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, Kuwata K, Masamune A, Ishihara S, Haga H, Kataoka K, Mii S, Shiraki Y, Ishikawa T, Ohno E, Kawashima H, Hirooka Y, Fujishiro M, Takahashi M, Enomoto A. Iida T, et al. Among authors: ishikawa t. Oncogene. 2022 May;41(19):2764-2777. doi: 10.1038/s41388-022-02288-9. Epub 2022 Apr 13. Oncogene. 2022. PMID: 35414659
Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial.
Minamizuka T, Koshizaka M, Shoji M, Yamaga M, Hayashi A, Ide K, Ide S, Kitamoto T, Sakamoto K, Hattori A, Ishikawa T, Kobayashi J, Maezawa Y, Kobayashi K, Takemoto M, Inagaki M, Endo A, Yokote K. Minamizuka T, et al. Among authors: ishikawa t. Asia Pac J Clin Nutr. 2021 Sep;30(3):424-435. doi: 10.6133/apjcn.202109_30(3).0009. Asia Pac J Clin Nutr. 2021. PMID: 34587702 Free article. Clinical Trial.
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: ishikawa t. Cancer Med. 2022 Oct;11(20):3796-3808. doi: 10.1002/cam4.4763. Epub 2022 Apr 19. Cancer Med. 2022. PMID: 35441477 Free PMC article.
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Aldrighetti L, Kudo M, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: ishikawa t. ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6. ESMO Open. 2022. PMID: 36208496 Free PMC article.
Increased Lung Uric Acid Deteriorates Pulmonary Arterial Hypertension.
Watanabe T, Ishikawa M, Abe K, Ishikawa T, Imakiire S, Masaki K, Hosokawa K, Fukuuchi T, Kaneko K, Ohtsubo T, Hirano M, Hirano K, Tsutsui H. Watanabe T, et al. Among authors: ishikawa t. J Am Heart Assoc. 2021 Dec 7;10(23):e022712. doi: 10.1161/JAHA.121.022712. Epub 2021 Nov 30. J Am Heart Assoc. 2021. PMID: 34845934 Free PMC article.
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: ishikawa t. Cancer Med. 2023 Jan;12(1):325-334. doi: 10.1002/cam4.4854. Epub 2022 Jun 3. Cancer Med. 2023. PMID: 35666040 Free PMC article.
7,180 results